Skip to content

RDW:MCHC as a Pragmatic Adjunct to SOFA Score in ICU Mortality Assessment

RDW:MCHC as a Pragmatic Adjunct to SOFA Score in ICU Mortality Assessment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07775911
Enrollment
200
Registered
2026-08-20
Start date
2026-07-05
Completion date
2026-08-05
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness

Brief summary

Critical illness represents a complex pathophysiological state characterized by systemic inflammation, oxidative stress, immune dysregulation, and progressive multiorgan dysfunction. In the Intensive Care Unit (ICU) setting, accurate and timely risk stratification remains paramount for optimizing patient outcomes, guiding therapeutic decision-making, and ensuring appropriate allocation of limited healthcare resources .Red cell distribution width (RDW), a quantitative measure of anisocytosis, has emerged as a powerful independent predictor of adverse outcomes across diverse clinical contexts, including sepsis, cardiovascular disease, and general ICU populations . Elevated RDW reflects dysregulated erythropoiesis and is mechanistically linked to chronic inflammation, oxidative stress, nutritional deficiencies, and impaired hematopoietic progenitor cell function .Mean corpuscular hemoglobin concentration (MCHC) represents the average hemoglobin concentration within erythrocytes and provides valuable information regarding red blood cell integrity, hemoglobin synthesis, and oxygen-carrying capacity. Reduced MCHC values are observed in conditions associated with impaired hemoglobin production, while elevated values may indicate hemolysis or red cell dehydration .Emerging evidence suggests that composite hematological ratios may enhance predictive performance compared to individual parameters by integrating complementary physiological information. The RDW:MCHC ratio is a novel biomarker that combines variability in red cell size with hemoglobin concentration, potentially offering a more comprehensive reflection of the underlying pathophysiological derangements characteristic of critical illness

Interventions

None listed

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* • ICU stay of at least 24 hours duration * Available complete blood count (CBC) parameters at the time * pregnant women at any gestational age and postpartum women (up to 6 weeks following delivery) are eligible * Adult patients (≥18 years)

Exclusion criteria

* • Documented hematological malignancies (including leukemia, lymphoma, and myelodysplastic syndromes) * Recent blood transfusion (within 7 days prior to ICU admission)

Design outcomes

Primary

MeasureTime frameDescription
1. ICU MortalityFrom ICU admission to ICU discharge or death, up to 90 daysAll-cause mortality during ICU stay, assessed through prospective follow-up from admission until discharge or death

Secondary

MeasureTime frameDescription
ICU Length of StayFrom ICU admission to ICU discharge (assessed up to 90 days)Duration of intensive care unit admission measured in days from ICU admission until ICU discharge.

Countries

Egypt

Contacts

PRINCIPAL_INVESTIGATORmarwa ELzanaty Elsayed, PHD

Sohag university .faculty of medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026